AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Financial Statements and ExhibitsItem 9.01 of Form 8-K, and this amendment should be read in conjunction with the Original Form 8-K.
| Item 9.01. | Financial Statements and Exhibits |
| (a) | Financial Statements of Business Acquired. |
The audited financial statements of Nuelle, Inc. as of June 30, 2016 and the related statements of operations, changes in stockholders’ deficit and cash flows for the year ended June 30, 2016, and the related independent auditors’ report of EKS&H LLLP together with the unaudited financial statements as of March 31, 2017 and the related statements of operations, changes in stockholders’ deficit and cash flows for the nine month period ended March 31, 2017 are filed as Exhibit 99.1 to this report and incorporated herein by reference.
| (b) | Pro Forma Financial Information. |
The unaudited pro forma combined statement of operations of Aytu BioScience, Inc. for the year ended June30, 2016 and the nine months ended March31, 2017, unaudited pro forma combined balance sheet as of March31, 2017, and the notes related thereto, are filed as Exhibit 99.2 to this report and incorporated herein by reference.
| Exhibit No. |
Description of Exhibit |
| 23.1 | Consent of EKS&H LLLP. |
| 99.1 | Audited financial statements of Nuelle, Inc. |
| 99.2 | Unaudited pro forma combined financial statements of Aytu BioScience, Inc. |
AYTU BIOSCIENCE, INC ExhibitEX-23.1 2 v471025_ex23-1.htm EXHIBIT 23.1 Exhibit 23.1 Consent of Independent Auditors We hereby consent to the incorporation by reference on Form 8-K/A (No. 000-53121) of Aytu BioScience,…To view the full exhibit click here
About AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU)
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.
